GWS
ALLO icon

Glassman Wealth Services’s Allogene Therapeutics ALLO Stock Holding History

Glassman Wealth Services’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-82
Closed -$1K – 1644
2022
Q1 		$1K Buy
+82
New +$854 ﹤0.01% 1313

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Glassman Wealth Services's ALLO Position: Q2 2022 in Review

Glassman Wealth Services sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 82 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in ALLO in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

  • Glassman Wealth Services reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 82 Allogene Therapeutics shares in Q2 2022, an estimated $1K.
  • Glassman Wealth Services first reported a position in Allogene Therapeutics in Q1 2022 and held it in 1 quarter.
  • Glassman Wealth Services's Allogene Therapeutics position peaked at $1K in Q1 2022.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on Glassman Wealth Services's 13F filing for Q2 2022, filed 4 Aug 2022.